🇺🇸 FDA
Patent

US 9828435

Use of antibodies or antigen-binding fragments thereof that specifically bind semaphorin-4D to increase tumor infiltrating leukocyte frequency

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 9828435 (Use of antibodies or antigen-binding fragments thereof that specifically bind semaphorin-4D to increase tumor infiltrating leukocyte frequency) held by VACCINEX, INC. expires Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
VACCINEX, INC.
Grant date
Tue Nov 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K2039/54, A61K2039/545